<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160468</url>
  </required_header>
  <id_info>
    <org_study_id>CF-301-105</org_study_id>
    <nct_id>NCT04160468</nct_id>
  </id_info>
  <brief_title>Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase</brief_title>
  <acronym>DISRUPT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraFect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraFect</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in
      addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of
      patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including
      right-sided infective endocarditis (IE). Patients will be randomized to receive a single
      intravenous dose of exebacase or placebo. Patients will receive SoCA selected by the
      investigators based on the protocol.

      Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus.
      Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in
      rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for
      resistance, and the potential to suppress antibiotic resistance when used together with
      antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the
      potential to improve clinical outcome when used in addition to SoCA to treat S. aureus BSI
      including IE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical responder rate at Day 14 in the methicillin-resistant Staphylococcus aureus (MRSA) population</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) through Day 60</measure>
    <time_frame>Through Day 60</time_frame>
    <description>TEAEs will be summarized by treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical responder rate at Day 14 in all S. aureus patients</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day survival in the MRSA population</measure>
    <time_frame>Through Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical responder rate at Day 60 in the MRSA population</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical responder rate at Day 60 in all S. aureus patients</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical responder rate at Day 60 in right-sided IE patients (all S. aureus and MRSA populations)</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <condition>Staphylococcus Aureus Endocarditis</condition>
  <arm_group>
    <arm_group_label>Exebacase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exebacase</intervention_name>
    <description>Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.</description>
    <arm_group_label>Exebacase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 12 years or older

          -  Blood culture positive for S. aureus

          -  At least two signs or symptoms attributable to S. aureus BSI/IE

          -  Known or suspected complicated S. aureus BSI and/or right-sided IE based on Modified
             Duke Criteria

          -  Not pregnant or breastfeeding and not of reproductive potential or agrees to remain
             abstinent or use contraception if of reproductive potential

        Exclusion Criteria:

          -  Previously received exebacase

          -  Known or suspected left-sided IE

          -  Treatment with effective systemic anti-staphylococcal antibiotic for more than 72
             hours within 7 days before randomization

          -  Presence of prosthetic valve or cardiac valve support ring, or presence of known or
             suspected infected orthopedic hardware, prosthetic joint, or cardiac device

          -  Known or suspected brain abscess or meningitis

          -  Known or suspected urinary tract infection or primary pneumonia as the sole source of
             S. aureus BSI

          -  Known polymicrobial BSI, or known ongoing systemic infection caused by other bacterial
             and/or fungal pathogen(s), and/or known to have COVID-19
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director, ContraFect</last_name>
    <phone>914-207-2300</phone>
    <email>clinicalstudies@contrafect.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-105 Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S. aureus bloodstream infection</keyword>
  <keyword>S. aureus bacteremia</keyword>
  <keyword>S. aureus right-sided infective endocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

